All the Active Ingredient Drugs
Interleukin Inhibitor, Monoclonal Antibody. Guselkumab 10 mg/ml. sol. for IV 10 mg/ml X 20 ml
IBD: Induction: 200-400 mg. Maint. 100-200 mg. See full prescr. info.
Ulcerative colitis: tmt. of adults with moder. to sev. active UC who have had an inadeq. response, lost response, or were intol. to either conventional ther., or a biologic tmt.
Crohn’s disease: tmt. of adults with moder. to sev. active CD who have had an inadeq. response, lost response, or were intol. to either conventional ther. or a biologic tmt.
C/I: Hypersens.
Interleukin Inhibitor, Monoclonal Antibody. Guselkumab 100 mg/ml. Pre-filled single syr. or pen with 1or 2 ml susp for SC inject.
Plaque psoriasis: 100 mg at Weeks 0 and 4, followed by a maint. dose every 8 weeks (q8w).
Psoriatic arthritis: 100 mg at Weeks 0 and 4, followed by a maint. dose every 8 weeks. For pts. at high risk for joint damage according to clin. judgement, a dose of 100 mg every 4 weeks (q4w) may be considered
IBD: Induction: 200-400 mg. Maint. 100-200 mg. See full prescr. info.
Plaque psoriasis: tmt. of adults with mod. to sev. plaque psoriasis who are candidates for syst. ther. or photother.
Psoriatic arthritis: alone or in comb. with methotrexate (MTX), for the tmt. of active psoriatic arthritis in adults who have had an inadeq. response or who have been intoler. to a prior disease-modifying antirheumatic drug (DMARD) ther.
Ulcerative colitis: tmt. of adults with moder. to sev. active UC who have had an inadeq. response, lost response, or were intol. to either conventional ther., or a biologic tmt.
Crohn’s disease: tmt. of adults with moder. to sev. active CD who have had an inadeq. response, lost response, or were intol. to either conventional ther. or a biologic tmt.
C/I: Hypersens.
